Abstract
Hypoactive sexual desire disorder (HSDD) is the most prevalent sexual dysfunction in women, and is marked by persistently diminished or absent desire for sexual activity accompanied by personal distress. In the United States, HSDD affects approximately 10% of women aged 18 to 44 years. Bremelanotide, a melanocortin receptor agonist and an analog of the endogenous neuropeptide α-melanocortin stimulating hormone, is approved for the treatment of acquired, generalized HSDD in premenopausal women. The RECONNECT studies (Studies 301 and 302), two identically designed, double-blind, randomized, placebo-controlled trials, demonstrated that subcutaneous self-administration of bremelanotide, as needed, significantly improved sexual desire and decreased personal distress in premenopausal women with HSDD. Effect size is important to consider, as it indicates the magnitude of change as a result of the intervention under review.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call